Braintree Says Suprep Case Doesn't Upend Drug Patent Law
Braintree Laboratories Inc. has urged the full Federal Circuit to reject Novel Laboratories Inc.'s argument that a panel decision in the companies' patent dispute over the colon cleanser Suprep flouted drug...To view the full article, register now.
Already a subscriber? Click here to view full article